Genezen, a Fishers, IN-based cell and gene therapy contract development and manufacturing organization (CDMO), raised $18.5M in Growth Equity funding.
The round was led by Ampersand Capital Partners.
The company intends to use the funds to expand its viral vector development and manufacturing capacity and capabilities.
Led by CEO and President Steven Favaloro, Genezen is a contract development and manufacturing organization (CDMO) which specializes in the supply of retroviral vectors, lentiviral vectors, and adeno-associated viral (AAV). The company recently completed qualification of its 25,000 sq ft GMP viral vector facility in Fishers, Indiana.
FinSMEs
02/11/2023